Dermatofibrosarcoma protuberans
MONDO:0011934Dermatofibrosarcoma protuberans (DFSP) is a rare infiltrating soft tissue sarcoma, generally of low grade malignancy, arising from the dermis of the skin and characteristically associated with a specific chromosomal translocation t(17;22).
Also known as: DFSP, dermatofibrosarcoma, dermatofibrosarcoma protuberans, familial dermatofibrosarcoma protuberans (subtype), giant cell fibroblastoma, metastatic dermatofibrosarcoma protuberans (subtype)
2829 clinical trials for this condition and its sub-types, 11 tagged with Dermatofibrosarcoma protuberans itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Dermatofibrosarcoma protuberans
-
Old drugs, new hope: imatinib combo tested for rare tumors
Disease control CompletedThis early-phase trial tested two cancer drugs—imatinib mesylate and cyclophosphamide—given daily by mouth to 26 people with rare, advanced tumors that had no standard treatment. The main goal was to find the safest dose of imatinib when combined with a fixed dose of cyclophospha…
Phase 1 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo targets Hard-to-Treat sarcomas
Disease control CompletedThis study tested a new drug called mecbotamab vedotin, alone or with the immunotherapy nivolumab, in 245 adults and teens aged 12+ with advanced solid tumors, including sarcomas. The goal was to check safety and see if the drug shrinks tumors. The trial is now complete, and resu…
Phase 1/2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC